These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28650274)

  • 1. Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate.
    Ainai A; Suzuki T; Tamura SI; Hasegawa H
    Viral Immunol; 2017; 30(6):451-462. PubMed ID: 28650274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
    Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.
    Terauchi Y; Sano K; Ainai A; Saito S; Taga Y; Ogawa-Goto K; Tamura SI; Odagiri T; Tashiro M; Fujieda M; Suzuki T; Hasegawa H
    Hum Vaccin Immunother; 2018 Jun; 14(6):1351-1361. PubMed ID: 29425074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
    Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
    Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
    J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
    Wu H; Bao Y; Wang X; Zhou D; Wu W
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized mucosal response to intranasal live attenuated influenza vaccine in adults.
    Barría MI; Garrido JL; Stein C; Scher E; Ge Y; Engel SM; Kraus TA; Banach D; Moran TM
    J Infect Dis; 2013 Jan; 207(1):115-24. PubMed ID: 23087433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal-subcutaneous prime-boost regimen for inactivated whole-virus influenza vaccine efficiently protects mice against both upper and lower respiratory tract infections.
    Shibuya M; Tamiya S; Kawai A; Yoshioka Y
    Biochem Biophys Res Commun; 2021 May; 554():166-172. PubMed ID: 33798943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.
    Sano K; Ainai A; Suzuki T; Hasegawa H
    Expert Rev Vaccines; 2018 Aug; 17(8):687-696. PubMed ID: 30092690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.
    Okamoto S; Matsuoka S; Takenaka N; Haredy AM; Tanimoto T; Gomi Y; Ishikawa T; Akagi T; Akashi M; Okuno Y; Mori Y; Yamanishi K
    Clin Vaccine Immunol; 2012 Jul; 19(7):979-90. PubMed ID: 22552600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine.
    Muszkat M; Greenbaum E; Ben-Yehuda A; Oster M; Yeu'l E; Heimann S; Levy R; Friedman G; Zakay-Rones Z
    Vaccine; 2003 Mar; 21(11-12):1180-6. PubMed ID: 12559796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.
    Ainai A; Tamura S; Suzuki T; van Riet E; Ito R; Odagiri T; Tashiro M; Kurata T; Hasegawa H
    Hum Vaccin Immunother; 2013 Sep; 9(9):1962-70. PubMed ID: 23896606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.
    Powers DC; Fries LF; Murphy BR; Thumar B; Clements ML
    J Clin Microbiol; 1991 Mar; 29(3):498-505. PubMed ID: 2037667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes.
    Moldoveanu Z; Clements ML; Prince SJ; Murphy BR; Mestecky J
    Vaccine; 1995 Aug; 13(11):1006-12. PubMed ID: 8525683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women.
    Brady RC; Jackson LA; Frey SE; Shane AL; Walter EB; Swamy GK; Schlaudecker EP; Szefer E; Wolff M; McNeal MM; Bernstein DI; Steinhoff MC
    Vaccine; 2018 Jul; 36(31):4663-4671. PubMed ID: 29961606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.